Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Molecular Partners ( (MOLN) ) has provided an announcement.
Molecular Partners has announced significant developments and future plans at the J.P. Morgan Healthcare Conference, highlighting its strategic focus on expanding its Radio-DARPin pipeline and clinical trials. In collaboration with Orano Med, the company will advance up to ten Radio-DARPin products, with the IND application for MP0712 targeting DLL3 expected to be submitted in the first half of 2025. Moreover, advances in its Switch-DARPin and MP0533 programs show promising results, with further studies and protocol amendments planned to enhance therapeutic outcomes. These steps are poised to reinforce Molecular Partners’ position in the biotech industry, particularly in oncology, offering potential benefits for stakeholders through innovative treatment options.
More about Molecular Partners
Molecular Partners AG is a clinical-stage biotech company focusing on the development of DARPin therapeutics, which are custom-built protein drugs designed to address medical challenges that other drug modalities cannot easily tackle. The company is primarily focused on oncology and has several programs in various stages of pre-clinical and clinical development. Founded in 2004, Molecular Partners operates from Zurich, Switzerland, and Concord, MA, USA, and collaborates with leading pharmaceutical companies to leverage the unique advantages of DARPins.
YTD Price Performance: 2.32%
Average Trading Volume: 25,147
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $200.2M
For an in-depth examination of MOLN stock, go to TipRanks’ Stock Analysis page.
